Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031
Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031 Report Finding & Highlights:
Global cancer peptide therapeutics market has transformed itself into a scientifically diverse yet active clinical field in cancer drug development due to its highly desirable potential for molecularly targeted and versatile cancer treatment modalities. Peptides hold a key position as they can be rationally designed to target and modulate complex cancer biology: receptor signaling pathways, intracellular protein interactions, cancer immune system targeting, and delivery to the tumor environment. As such, they represent a significant aspect of the next generation oncology research and development market.
In this report, we undertake a comprehensive analysis of global cancer peptide therapeutics market, highlighting clinical development efforts, partnership and collaboration activities, investment trends, and the development of novel scientific avenues, all aimed at assisting investors, pharmaceutical companies and stakeholders make their decision in the cancer treatment landscape with an effective use of peptide based innovative approaches.
Clinical Development Insight Included In Report
The report offers an extensive analysis of current oncology programs involving peptides at various levels of clinical development, starting with the first human studies to advanced stages and even registration studies, as well as the further assessment of already existing peptide therapies. The scope of clinical trials covers various cancer types, both commonly encountered and quite rare ones, thus demonstrating the increasing importance of peptide based solutions in oncology treatment.
The analysis also covers the important characteristics of these clinical trials, including whether monotherapy or combinations were used, targeted patient populations, lines of therapy, routes of administration, clinical trial designs, sponsoring organizations, development partners, and licensing agreements. The report also provides an assessment of the results achieved in terms of efficacy and safety from clinical trials using peptides in oncology therapies, specifically focusing on the percentage of responders, progression free survival rates, and overall survival figures. It further evaluates the potential for peptides to be used in combination therapies with chemotherapy, immunotherapies, and other antineoplastic treatments.
Major Companies Driving Peptide Therapeutics R&D
In this regard, the peptide oncology landscape includes strong contributions from big pharma companies as well as small biotechnology firms. In particular, significant involvement of companies like Eli Lilly and Novartis in peptide based approaches through licensing, partnerships, and radioligand development programs can be observed. Peptide based techniques are currently used by these companies in the framework of their comprehensive oncology pipelines as part of combination approaches or targeted treatment strategies for a wide variety of cancers.
Additionally, smaller biotechnology companies like Avacta Therapeutics and Gate2Brain have been actively developing promising peptide based anticancer compounds in preclinical and clinical studies. Such companies have been collaborating with more mature players on translating novel peptides into treatment candidates within the field. The involvement of big pharma in this field, together with the innovative efforts of emerging biotechnology firms, ensures ongoing progress in peptide oncology.
Report Indicating Future Development Of Cancer Peptide Therapeutics
This report outlines an organized assessment of the ongoing development of peptide therapies against cancer, detailing developments from early research programs through to clinical trials and even to later stage validation studies. Peptides continue to demonstrate increasing utility in targeting multiple cancers, ranging from more common solid cancers to some of the rarer forms. One particular area of interest is the use of synthetic peptides in targeting protein–protein interactions within the cell and oncogenic signal transduction pathways involved in driving tumor proliferation and survival.
Moreover, developments in tumor penetration and delivery of peptides in cancer are noted, along with efforts towards improving selectivity within the tumor environment without causing toxicity to other parts of the body. In addition, developments in the peptide based immunotherapy approaches, including those targeting T-cell proliferation and stimulation, have been discussed, alongside peptide guidance of radiopharmaceuticals to tumors. Overall, this shows a wide range of ongoing progress in the field of peptide therapy in oncology
- Research Methodology
- Global Cancer Peptide Drug Market Opportunity: > USD 25 Billion By 2031
- Global & Regional Market trends Insight
- Insight On Cancer Peptides In Clinical Trials: > 240 Drugs
- Cancer Peptide Clinical Trials Insight By Company, Country, Indication & Phase
- Number Of Approved Cancer Peptides: > 30 Drugs
- Insight On Approved Cancer Peptide By Brand Name, Indication, Company, Location, Collaborations
- Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
- Venom Peptides As New Opportunity For Cancer Peptide Therapy
Global cancer peptide therapeutics market has transformed itself into a scientifically diverse yet active clinical field in cancer drug development due to its highly desirable potential for molecularly targeted and versatile cancer treatment modalities. Peptides hold a key position as they can be rationally designed to target and modulate complex cancer biology: receptor signaling pathways, intracellular protein interactions, cancer immune system targeting, and delivery to the tumor environment. As such, they represent a significant aspect of the next generation oncology research and development market.
In this report, we undertake a comprehensive analysis of global cancer peptide therapeutics market, highlighting clinical development efforts, partnership and collaboration activities, investment trends, and the development of novel scientific avenues, all aimed at assisting investors, pharmaceutical companies and stakeholders make their decision in the cancer treatment landscape with an effective use of peptide based innovative approaches.
Clinical Development Insight Included In Report
The report offers an extensive analysis of current oncology programs involving peptides at various levels of clinical development, starting with the first human studies to advanced stages and even registration studies, as well as the further assessment of already existing peptide therapies. The scope of clinical trials covers various cancer types, both commonly encountered and quite rare ones, thus demonstrating the increasing importance of peptide based solutions in oncology treatment.
The analysis also covers the important characteristics of these clinical trials, including whether monotherapy or combinations were used, targeted patient populations, lines of therapy, routes of administration, clinical trial designs, sponsoring organizations, development partners, and licensing agreements. The report also provides an assessment of the results achieved in terms of efficacy and safety from clinical trials using peptides in oncology therapies, specifically focusing on the percentage of responders, progression free survival rates, and overall survival figures. It further evaluates the potential for peptides to be used in combination therapies with chemotherapy, immunotherapies, and other antineoplastic treatments.
Major Companies Driving Peptide Therapeutics R&D
In this regard, the peptide oncology landscape includes strong contributions from big pharma companies as well as small biotechnology firms. In particular, significant involvement of companies like Eli Lilly and Novartis in peptide based approaches through licensing, partnerships, and radioligand development programs can be observed. Peptide based techniques are currently used by these companies in the framework of their comprehensive oncology pipelines as part of combination approaches or targeted treatment strategies for a wide variety of cancers.
Additionally, smaller biotechnology companies like Avacta Therapeutics and Gate2Brain have been actively developing promising peptide based anticancer compounds in preclinical and clinical studies. Such companies have been collaborating with more mature players on translating novel peptides into treatment candidates within the field. The involvement of big pharma in this field, together with the innovative efforts of emerging biotechnology firms, ensures ongoing progress in peptide oncology.
Report Indicating Future Development Of Cancer Peptide Therapeutics
This report outlines an organized assessment of the ongoing development of peptide therapies against cancer, detailing developments from early research programs through to clinical trials and even to later stage validation studies. Peptides continue to demonstrate increasing utility in targeting multiple cancers, ranging from more common solid cancers to some of the rarer forms. One particular area of interest is the use of synthetic peptides in targeting protein–protein interactions within the cell and oncogenic signal transduction pathways involved in driving tumor proliferation and survival.
Moreover, developments in tumor penetration and delivery of peptides in cancer are noted, along with efforts towards improving selectivity within the tumor environment without causing toxicity to other parts of the body. In addition, developments in the peptide based immunotherapy approaches, including those targeting T-cell proliferation and stimulation, have been discussed, alongside peptide guidance of radiopharmaceuticals to tumors. Overall, this shows a wide range of ongoing progress in the field of peptide therapy in oncology
1. INTRODUCTION TO PEPTIDE THERAPEUTICS
1.1 Overview Of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing & Functioning of Peptide Drugs
1.4 Significance Of Peptides As Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy
2. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS
2.1 Hormonal Peptides
2.2 Peptide Based Radionuclide Drug Carriers
2.3 Peptide Vaccines
2.4 Cytotoxic Drug Carriers
2.5 Anticancer Peptides
2.6 Tumor-Targeting and Cell-Penetrating Peptides
2.7 Peptide Nanomedicines
2.8 Receptor Antagonist and PPI-Modulating Peptides
2.9 Emerging Approaches
3. GLOBAL CANCER PEPTIDE DRUG MARKET INSIGHT
3.1 Current Market Scenario
3.2 Future Market Opportunities
4. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY COUNTRY
4.1 US
4.2 China
4.3 Europe
4.4 Canada
4.5 UK
4.6 Australia
4.7 Japan
4.8 South Korea
4.9 India
4.10 Middle East
4.11 Latin America
5. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY INDICATION
5.1 Breast Cancer
5.2 Hematological Malignancies
5.3 Urothelial Cancer
5.4 Prostate Cancer
5.5 Lung Cancer
5.6 Skin Cancer
5.7 Gastrointestinal Cancer
5.8 Gynecological Cancer
5.9 CNS Cancers
6. MARKETED CANCER PEPTIDES DRUGS & GENERICS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT
6.1 Firmagon (Degarelix)
6.1 Eligard (Leuprolide)
6.2 Lupron (Leuprolide Acetate)
6.3 Gonax (Degarelix Acetate)
6.4 Trelstar (Triptorelin)
6.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
6.6 Velcade (Bortizomib)
6.7 Ninlaro (Ixazomib)
6.8 Kyprolis (Carfilzomib)
6.9 Istodax (Romidepsin)
6.10 Zoladex (Goserelin)
6.11 Cosmegen (Dactinomycin)
6.12 Somatuline Depot (Lanreotide)
6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
6.14 Bynfezia Pen (Octreotide)
6.15 Lutathera (Lutetium Lu 177 dotatate)
6.16 Mepact (Mifamurtide)
6.17 Netspot (Gallium Ga 68 dotatate)
6.18 Camcevi (Leuprolide)
7. MARKETED CANCER PEPTIDES DRUGS SALES INSIGHT
7.1 Kyprolis
7.2 Zoladex
7.3 Lutathera
7.4 Sandostatin
7.5 Somatuline
7.6 Decapeptyl SR
7.7 Ninlaro
7.8 Velcade
7.9 Lupron
8. GLOBAL PEPTIDE CANCER DRUGS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase II/III
8.8 Phase III
8.9 Preregistration
8.10 Registered
9. MARKETED PEPTIDE CANCER DRUGS CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION
10. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY
10.1 Bee Venom-Derived Peptides
10.2 Scorpion Venom-Derived Peptides
10.3 Snake Venom-Derived Peptides
10.4 Spider Venom-Derived Peptides
10.5 Cone Snail Venom-Derived Peptides
11. GLOBAL PEPTIDE CANCER DRUG MARKET DYNAMICS
11.1 Favorable Market Parameters & Opportunities
11.2 Commercialization Challenges & Strategic Solutions
12. THERAPEUTIC PEPTIDE TARGETS
12.1 Signal Transduction Pathways
12.2 Cell Cycle Regulators
12.3 Apoptosis/Cell-Death Modulators
12.4 Tumor Suppressor Targeting peptides
12.5 Transcription Factor-Targeting Peptides
12.6 DNA Repair Pathway Inhibitors
12.7 Anti-Angiogenic Peptides
12.8 Immunomodulatory Peptides
12.9 Membrane-Disrupting/Oncolytic Peptides
13. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS
13.1 Peptide Therapeutics v/s Chemotherapy
13.2 Peptide Therapeutics vs Immunotherapies
13.3 Peptide Therapeutics vs Gene Therapy
14. COMPETITIVE LANDSCAPE
14.1 3B Pharmaceuticals
14.2 APIM Therapeutics
14.3 AsclepiX Therapeutics
14.4 Bicycle Therapeutics
14.5 Biohaven Labs
14.6 BrightPath Biotherapeutics
14.7 Bristol-Myers Squibb
14.8 Gnubiotics Sciences
14.9 IDP Pharma
14.10 Janux Therapeutics
14.11 Medikine
14.12 Modulation Therapeutics
14.13 Novartis
14.14 Oncopeptides
14.15 Parabilis Medicines
14.16 PeptiDream
14.17 Perspective Therapeutics
14.18 Pharm-Sintez
14.19 Sapience Therapeutics
14.20 Vigeo Therapeutics
1.1 Overview Of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing & Functioning of Peptide Drugs
1.4 Significance Of Peptides As Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy
2. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS
2.1 Hormonal Peptides
2.2 Peptide Based Radionuclide Drug Carriers
2.3 Peptide Vaccines
2.4 Cytotoxic Drug Carriers
2.5 Anticancer Peptides
2.6 Tumor-Targeting and Cell-Penetrating Peptides
2.7 Peptide Nanomedicines
2.8 Receptor Antagonist and PPI-Modulating Peptides
2.9 Emerging Approaches
3. GLOBAL CANCER PEPTIDE DRUG MARKET INSIGHT
3.1 Current Market Scenario
3.2 Future Market Opportunities
4. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY COUNTRY
4.1 US
4.2 China
4.3 Europe
4.4 Canada
4.5 UK
4.6 Australia
4.7 Japan
4.8 South Korea
4.9 India
4.10 Middle East
4.11 Latin America
5. CANCER PEPTIDE RESEARCH & MARKET TRENDS BY INDICATION
5.1 Breast Cancer
5.2 Hematological Malignancies
5.3 Urothelial Cancer
5.4 Prostate Cancer
5.5 Lung Cancer
5.6 Skin Cancer
5.7 Gastrointestinal Cancer
5.8 Gynecological Cancer
5.9 CNS Cancers
6. MARKETED CANCER PEPTIDES DRUGS & GENERICS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT
6.1 Firmagon (Degarelix)
6.1 Eligard (Leuprolide)
6.2 Lupron (Leuprolide Acetate)
6.3 Gonax (Degarelix Acetate)
6.4 Trelstar (Triptorelin)
6.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
6.6 Velcade (Bortizomib)
6.7 Ninlaro (Ixazomib)
6.8 Kyprolis (Carfilzomib)
6.9 Istodax (Romidepsin)
6.10 Zoladex (Goserelin)
6.11 Cosmegen (Dactinomycin)
6.12 Somatuline Depot (Lanreotide)
6.13 Sandostatin/ Sandostatin LAR (Octreotide Acetate)
6.14 Bynfezia Pen (Octreotide)
6.15 Lutathera (Lutetium Lu 177 dotatate)
6.16 Mepact (Mifamurtide)
6.17 Netspot (Gallium Ga 68 dotatate)
6.18 Camcevi (Leuprolide)
7. MARKETED CANCER PEPTIDES DRUGS SALES INSIGHT
7.1 Kyprolis
7.2 Zoladex
7.3 Lutathera
7.4 Sandostatin
7.5 Somatuline
7.6 Decapeptyl SR
7.7 Ninlaro
7.8 Velcade
7.9 Lupron
8. GLOBAL PEPTIDE CANCER DRUGS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
8.1 Research
8.2 Preclinical
8.3 Phase
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase II/III
8.8 Phase III
8.9 Preregistration
8.10 Registered
9. MARKETED PEPTIDE CANCER DRUGS CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION
10. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY
10.1 Bee Venom-Derived Peptides
10.2 Scorpion Venom-Derived Peptides
10.3 Snake Venom-Derived Peptides
10.4 Spider Venom-Derived Peptides
10.5 Cone Snail Venom-Derived Peptides
11. GLOBAL PEPTIDE CANCER DRUG MARKET DYNAMICS
11.1 Favorable Market Parameters & Opportunities
11.2 Commercialization Challenges & Strategic Solutions
12. THERAPEUTIC PEPTIDE TARGETS
12.1 Signal Transduction Pathways
12.2 Cell Cycle Regulators
12.3 Apoptosis/Cell-Death Modulators
12.4 Tumor Suppressor Targeting peptides
12.5 Transcription Factor-Targeting Peptides
12.6 DNA Repair Pathway Inhibitors
12.7 Anti-Angiogenic Peptides
12.8 Immunomodulatory Peptides
12.9 Membrane-Disrupting/Oncolytic Peptides
13. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS
13.1 Peptide Therapeutics v/s Chemotherapy
13.2 Peptide Therapeutics vs Immunotherapies
13.3 Peptide Therapeutics vs Gene Therapy
14. COMPETITIVE LANDSCAPE
14.1 3B Pharmaceuticals
14.2 APIM Therapeutics
14.3 AsclepiX Therapeutics
14.4 Bicycle Therapeutics
14.5 Biohaven Labs
14.6 BrightPath Biotherapeutics
14.7 Bristol-Myers Squibb
14.8 Gnubiotics Sciences
14.9 IDP Pharma
14.10 Janux Therapeutics
14.11 Medikine
14.12 Modulation Therapeutics
14.13 Novartis
14.14 Oncopeptides
14.15 Parabilis Medicines
14.16 PeptiDream
14.17 Perspective Therapeutics
14.18 Pharm-Sintez
14.19 Sapience Therapeutics
14.20 Vigeo Therapeutics
LIST OF FIGURES
Figure 1-1: Functional Role Of Peptides In The Human Body
Figure 1-2: Historical Timeline Of Peptide Therapeutics
Figure 1-3: Anticancer Peptides - Classification
Figure 1-4: Traditional Structure-Based Design Strategies Used In Peptide Drug Discovery
Figure 1-5: Peptides - Significance As Cancer Therapeutics
Figure 1-6: Peptides - Role In Cancer Immunotherapy
Figure 2-1: Hormonal Peptides In Cancer Therapy
Figure 2-2: GnRH Therapy Mechanism
Figure 2-3: Somatostatin-Based Targeted Therapy
Figure 2-4: GHRH–IGF Axis
Figure 2-5: Peptide Radiopharmaceutical Structure
Figure 2-6: Peptide-Based Radionuclide Drug Carriers
Figure 2-7: Theranostic Workflow
Figure 2-8: Peptide Vaccine Immunotherapy
Figure 2-9: Peptide-Based Drug Delivery In Cancer
Figure 2-10: Structural Classification Of Anticancer Peptides
Figure 2-11: Mechanistic Overview Of Anticancer Peptides
Figure 2-12: Functional Roles Of Tumor-Targeting Peptides & Cell-Penetrating Peptides In Cancer Therapy
Figure 2-13: Major Internalization Pathways Of Cell-Penetrating Peptides
Figure 2-14: Design Of Bifunctional Peptide Constructs
Figure 2-15: Activatable Cell-Penetrating Peptide Strategy
Figure 2-16: Integration Of Peptides & Nanotechnology For Precision Oncology
Figure 2-17: Classification Of Receptor Antagonist & PPI-Modulating Peptides
Figure 2-18: Inhibition Of Oncogenic Protein–Protein Interactions
Figure 2-19: Modern Technologies For Peptide Discovery
Figure 2-20: Stabilization Of ?-Helical Peptides By Stapling
Figure 2-21: Structural Advantages Of Cyclic Peptide Therapeutics
Figure 2-22: Foldamer-Based Mimics Of Protein Secondary Structures
Figure 2-23: Artificial Intelligence-Driven Next-Generation Peptide Design
Figure 3-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2024 - 2031
Figure 3-2: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2024 - 2031
Figure 3-3: Global Cancer Peptide Therapeutics Market – Future Opportunities
Figure 5-1: 17-328 Phase 1 (NCT03362060) Study – Initiation & Completion Year
Figure 5-2: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-3: PQ203-001 Phase 1 (NCT07190469) Study – Initiation & Completion Year
Figure 5-4: NCI-2014-02621 Phase 1 (NCT02334865) Study – Initiation & Completion Year
Figure 5-5: 20190675 Phase 1 (NCT04365179) Study – Initiation & Completion Year
Figure 5-6: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year
Figure 5-7: 202412028 Phase 1 (NCT06529822) Study – Initiation & Completion Year
Figure 5-8: PRMC 20-027 Phase 1 (NCT05010200) Study – Initiation & Completion Year
Figure 5-9: TB001 Version 2.1_2024-10-25 Phase 1/2 (NCT06400160) Study – Initiation & Completion Year
Figure 5-10: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year
Figure 5-11: CFXX489A12101 Phase 1 (NCT06562192) Study – Initiation & Completion Year
Figure 5-12: CGCJ904A12101 Phase 1 (NCT07261631) Study – Initiation & Completion Year
Figure 5-13: NCI-2017-01781 Phase 1 (NCT03300817) Study – Initiation & Completion Year
Figure 5-14: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-15: NeoLIPA Phase 2 (NCT06651151) Study – Initiation & Completion Year
Figure 5-16: KEYNOTE-D18 Phase 3 (NCT05155254) Study – Initiation & Completion Year
Figure 5-17: ST316-101 Phase 1 (NCT05848739) Study – Initiation & Completion Year
Figure 5-18: FOG-001-101 Phase 1/2 (NCT05919264) Study – Initiation & Completion Year
Figure 5-19: RYZ801-101 Phase 1/2 (NCT06726161) Study – Initiation & Completion Year
Figure 5-20: AMPLIFY-7P Phase 1/2 (NCT05726864) Study – Initiation & Completion Year
Figure 5-21: CDMRP-CA170223 Phase 2 (NCT03796884) Study – Initiation & Completion Year
Figure 5-22: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-23: CBX-12-201 Phase 2 (NCT06315491) Study – Initiation & Completion Year
Figure 5-24: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year
Figure 5-25: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year
Figure 5-26: NCI-2015-00694 Phase 2 (NCT02455557) Study – Initiation & Completion Year
Figure 5-27: INTERCEPT-H3 Phase 1 (NCT04808245) Study – Initiation & Completion Year
Figure 5-28: ViCTOry Phase 1 (NCT05609994) Study – Initiation & Completion Year
Figure 5-29: NeoVax Phase 1 (NCT02287428) Study – Initiation & Completion Year
Figure 5-30: PRiME Phase 1 (NCT03299309) Study – Initiation & Completion Year
Figure 5-31: ST101-101 Phase 1/2 (NCT04478279) Study – Initiation & Completion Year
Figure 6-1: Firmagon – Patent Issue & Expiration Years
Figure 6-2: Firmagon – Price Per Unit & Supply Of Powder For Subcutaneous Injection (US$), June’2026
Figure 6-3: Firmagon - Starting & Maintenance Dosage (mg)
Figure 6-4: Firmagon – Treatment Costs Of Initial Cycle & Maintenance Cycle (US$), June’2026
Figure 6-5: Eligard - Cost Of Subcutaneous Powder For Injection By Dose (US$), June’2026
Figure 6-6: Eligard – Recommended Dosage For Prostate Cancer On Monthly Basis (mg)
Figure 6-7: Eligard – Prostate Cancer Annual Treatment Cost By Dose (US$), June’2026
Figure 6-8: Lupron Sustained Release Preparation – Patent Issue & Expiration Year
Figure 6-9: Lupron – Price Of Lupron Depot Intramuscular Kits (US$), June’2026
Figure 6-10: Lupron – Price of Lupron Depot Intramuscular Powder By Dose (US$), June’2026
Figure 6-11: Lupron – Annual Treatment Costs By Intramuscular Kit Dose (US$), June’2026
Figure 6-12: Lupron – Annual Treatment Costs By Intramuscular Powder Dose (US$), June’2026
Figure 6-13: Gonax - Cost of Supply Of Powder For Subcutaneous Injection (US$), June’2026
Figure 6-14: Gonax - Starting & Maintenance Dosage (mg)
Figure 6-15: Trelstar – Patent Issue & Expiration Year
Figure 6-16: Trelstar - Cost Per Unit & Supply Of Powder For Intramuscular Injection (US$), June’2026
Figure 6-17: Trelstar – Annual Treatment Cost By Dose (US$), June’2026
Figure 6-18: Decapeptyl SR – Price For A Supply of 3mg, 11.25mg & 22.5mg Powder For Injection (GBP/US$), June’2026
Figure 6-19: Decapeptyl SR - Recommended Dosage For Prostate Cancer (mg/week)
Figure 6-20: Decapeptyl SR - Annual Prostate Cancer Treatment Cost By Dose (US$), June’2026
Figure 6-21: Velcade – Price Of 3.5 mg Powder For Injection (US$), June’2026
Figure 6-22: Bortizomib – Price Of Injectable Powder For Injection By Dose (US$), June’2026
Figure 6-23: Ninlaro – Patent Issue & Expiration Year
Figure 6-24: US & EU – Price Per Unit & Supply Of Ninlaro Capsule (US$), June’2026
Figure 6-25: Ninlaro – Recommended Dose & Dose Reductions For Multiple Myeloma Treatment (mg/week)
Figure 6-26: Kyprolis – Price Of 10mg, 30mg & 60mg Intravenous Powder For Injection (US$), June’2026
Figure 6-27: Kyprolis – Initial Dose & Maintenance Dose For Multiple Myeloma Treatment (mg/m2/week)
Figure 6-28: Kyprolis - Initial Dose & Maintenance Dose As Monotherapy For Multiple Myeloma Treatment (mg/m2 Twice a Week)
Figure 6-29: Romidepsin – FDA Approval Year By Indication
Figure 6-30: Istodax & Romidepsin – Price Per Supply Of Intravenous Powder (US$), June’2026
Figure 6-31: Zoladex - Cost Of Implant By Dose (US$), June’2026
Figure 6-32: Zoladex – Recommended Dose For Prostate Cancer Management On Monthly Basis (mg/week)
Figure 6-33: Zoladex – Annual Treatment Cost Using 3.6mg & 10.8mg Implant (US$), June’2026
Figure 6-34: Dactinomycin – Price For Generic & Branded 0.5 mg Powder For Injection (US$), June’2026
Figure 6-35: Somatuline Depot – Price Per Unit & supply of Subcutaneous Solution By Dose (US$), June’2026
Figure 6-36: Lanreotide – Price Per Unit & Supply Of Subcutaneous Solution (US$), June’2026
Figure 6-37: Somatuline Depot – Treatment Cost Of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), June’2026
Figure 6-38: Sandostatin – Price Per Unit & 10-Vial Supply By Dose (US$), June’2026
Figure 6-39: Sandostatin LAR – Price Of Intramuscular Powder For Injection By Dose (US$), June’2026
Figure 6-40: Octreotide – Price Per Unit & Supply Of 10 mL Injectable Solution (US$), June’2026
Figure 6-41: Octreotide – Price Per Unit & Supply Of 5 mL Injectable Solution (US$), June’2026
Figure 6-42: Octreotide – Price Per Unit & Supply Of Intramuscular Powder For Injection By Dose (US$), June’2026
Figure 6-43: Sandostatin - Mean Initial Dose For Treatment Of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg/day)
Figure 6-44: Bynfezia Pen – Patent Issue & Expiration Year
Figure 6-45: Bynfezia Pen – Price Per Unit & Supply Of Subcutaneous Solution (US$), June’2026
Figure 6-46: Bynfezia Pen – Mean Dose For First 2 Week & Subsequent Weeks (mcg/day)
Figure 6-47: Lutathera – Patent Issue & Expiration Years
Figure 6-48: Lutathera – RDP & ODE Regional Expiry Years
Figure 6-49: Mepact - Recommended Number Of Dose Administration/Week for 12 & 24 Weeks Treatment
Figure 7-1: Kyprolis – Global Sales (US$ Million), 2020-2026
Figure 7-2: Kyprolis – Global Sales By Region (US$ Million), Q1’2026
Figure 7-3: Kyprolis – Global Sales By Region (US$ Million), 2025
Figure 7-4: Kyprolis - US Annual Sales (US$ Million), 2020-2026
Figure 7-5: Kyprolis - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-6: Zoladex - Global Sales (US$ Million), 2020-2026
Figure 7-7: Zoladex - Global Sales By Region (US$ Million), Q1’2026
Figure 7-8: Zoladex - Global Sales By Region (US$ Million), 2025
Figure 7-9: Zoladex - US Annual Sales (US$ Million), 2020-2026
Figure 7-10: Zoladex – Europe Annual Sales (US$ Million), 2020-2026
Figure 7-11: Zoladex – Emerging Markets Annual Sales (US$ Million), 2020-2026
Figure 7-12: Zoladex - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-13: Lutathera - Global Sales (US$ Million), 2020-2026
Figure 7-14: Lutathera - Global Sales By Region (US$ Million), 2024–2026
Figure 7-15: Lutathera – Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-16: Lutathera - US Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-17: Lutathera - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-18: Sandostatin - Global Sales (US$ Million), 2020-2026
Figure 7-19: Sandostatin - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-20: Sandostatin - US Annual Sales (US$ Million), 2020-2026
Figure 7-21: Sandostatin - US Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-22: Sandostatin - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-23: Sandostatin - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-24: Somatuline – Global Sales (US$ Million), 2020-2026
Figure 7-25: Somatuline - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-26: Somatuline – North America Sales (US$ Million), 2022-2026
Figure 7-27: Somatuline - NA Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-28: Somatuline – Europe Sales (US$ Million), 2022-2026
Figure 7-29: Somatuline - Europe Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-30: Somatuline – ROW Sales (US$ Million), 2022-2026
Figure 7-31: Somatuline - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-32: Decapeptyl – Global Sales (US$ Million), 2020-2026
Figure 7-33: Decapeptyl - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-34: Decapeptyl – Europe Sales (US$ Million), 2022-2026
Figure 7-35: Decapeptyl - Europe Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-36: Decapeptyl – ROW Sales (US$ Million), 2022-2026
Figure 7-37: Decapeptyl - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-38: Ninlaro – Global Sales (US$ Million), 2020-2026
Figure 7-39: Ninlaro - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-40: Velcade - Global Sales (US$ Million), 2020-2024
Figure 7-41: Velcade - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 7-42: Global - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-43: US - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-44: ROW - Lupron Annual Sales (US$ Million), 2019-2021
Figure 8-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2026
Figure 10-1: Venom-Derived Peptides In Cancer Therapy
Figure 10-2: Bee Venom-Derived Peptides In Cancer Therapy
Figure 10-3: Melittin - Mechanism Of Action
Figure 10-4: Scorpion Venom-Derived Peptides In Cancer Therapy
Figure 10-5: Hallmarks Of Cancer Targeted By Scorpion Venom Peptides
Figure 10-6: Snake Venom-Derived Peptides As Anticancer Agents
Figure 10-7: Spider Venom-Derived Peptides In Cancer Therapy
Figure 10-8: Nanotechnology-Enhanced Lycosin-I Therapy
Figure 10-9: Cone Snail Venom-Derived Peptides In Cancer Therapy
Figure 11-1: Global Peptide Cancer Drug Market - Drivers & Opportunities
Figure 11-2: Global Peptide Cancer Drug Market - Key Challenges & Corresponding Solutions
Figure 12-1: Classification & Molecular Targets of Anticancer Therapeutic Peptides
Figure 12-2: Therapeutic Peptide Targets In Cancer Signal Transduction Networks
Figure 12-3: Cell Cycle & Major Peptide Intervention Points
Figure 12-4: Checkpoint & Mitotic Targets For Therapeutic Peptides
Figure 12-5: Major Peptide Targets In Apoptosis Signaling
Figure 12-6: BH3 Mimetic Mechanism
Figure 12-7: Transcription Factor-Targeting Peptides In Cancer
Figure 12-8: Mechanisms Of Peptide Inhibition Of Transcription Factors
Figure 12-9: Dominant-Negative Peptide Strategy
Figure 12-10: Challenges & Solutions In Transcription Factor Peptide Therapy
Figure 12-11: DNA Damage Response & Sites Of Peptide Intervention
Figure 12-12: Synthetic Lethality In DNA Repair
Figure 12-13: Anti-Angiogenic Peptides – Examples
Figure 12-14: Anti-Angiogenic Peptides - Classification
Figure 12-15: Overall Mechanism Of Immunomodulatory Peptides
Figure 12-16: Dual Action Pathway
Figure 12-17: Membrane-Disrupting Peptides - Overall Mechanism
Figure 12-18: Cancer Selectivity Mechanism
List Of Tables
Table 1-1: Source Or Chemical Nature Of Early Peptides
Table 2-1: Classification Of Hormonal Peptide Therapeutics
Table 2-2: Major Receptor Targets For Peptide Radionuclide Delivery
Table 2-3: Types Of Peptide Cancer Vaccines
Table 2-4: Common Cytotoxic Payloads
Table 2-5: Types Of Peptide-Based Drug Delivery Systems
Table 2-6: Classification Of Cell-Penetrating Peptides
Table 2-7: Comparison Between TTPs & CPPs
Table 2-8: Stimuli-Responsive Peptide Nanomedicine Systems
Table 2-9: Nanocarrier Platforms In Peptide Nanomedicine
Table 2-10: Comparison Of Conventional Drug Delivery & Peptide Nanomedicine
Table 2-11: Peptide Engineering Strategies For PPI Inhibitors
Table 2-12: Types Of PPI-Modulating Peptides
Table 2-13: Comparison Of PPI-Modulating Peptides & Receptor Antagonist Peptides
Table 2-14: Limitations Addressed By Emerging Peptide Therapeutics
Table 2-15: Comparison Of Emerging Peptide Platforms
Table 2-16: Artificial Intelligence Tools In Peptide Design
Table 2-17: Advantages Of AI-Guided Peptide Discovery
Table 3-1: Global Cancer Peptide Therapeutics Market – Recent Fundings & Investments
Table 3-2: Global Cancer Peptide Therapeutics Market – Recent Collaborations
Table 6-1: Trelstar - Recommended Dose (mg/week)
Table 6-2: Velcade - Dosage Regimen For Patients With Previously Untreated Multiple Myeloma
Table 6-3: Kyprolis –Expiration Year Of Patents
Table 10-1: Broad Classification Of Venom Sources For ACPs
Table 10-2: Most Common Venom Sources Investigated For Anticancer Peptides
Table 10-3: Well-Known Venom-Derived Anticancer Peptides & Their Mechanisms
Table 10-4: Major Bee Venom Peptides & Their Anticancer Functions
Table 10-5: Major Scorpion Venom Peptides & Their Anticancer Activities
Table 10-6: Major Snake Venom-Derived Anticancer Peptides
Table 10-7: Major Spider Venom-Derived Anticancer Peptides
Table 10-8: Major Cone Snail Venom Peptides & Anticancer Activities
Table 12-1: MAPK Signaling Components Targeted By Therapeutic Peptides
Table 12-2: Major Signal Transduction Pathways & Their Cancer Functions
Table 12-3: Delivery & Engineering Strategies For Cell Cycle Peptides
Table 12-4: DNA Repair Targets & Therapeutic Outcomes
Table 12-5: Types Of Immunomodulatory Peptides
Figure 1-1: Functional Role Of Peptides In The Human Body
Figure 1-2: Historical Timeline Of Peptide Therapeutics
Figure 1-3: Anticancer Peptides - Classification
Figure 1-4: Traditional Structure-Based Design Strategies Used In Peptide Drug Discovery
Figure 1-5: Peptides - Significance As Cancer Therapeutics
Figure 1-6: Peptides - Role In Cancer Immunotherapy
Figure 2-1: Hormonal Peptides In Cancer Therapy
Figure 2-2: GnRH Therapy Mechanism
Figure 2-3: Somatostatin-Based Targeted Therapy
Figure 2-4: GHRH–IGF Axis
Figure 2-5: Peptide Radiopharmaceutical Structure
Figure 2-6: Peptide-Based Radionuclide Drug Carriers
Figure 2-7: Theranostic Workflow
Figure 2-8: Peptide Vaccine Immunotherapy
Figure 2-9: Peptide-Based Drug Delivery In Cancer
Figure 2-10: Structural Classification Of Anticancer Peptides
Figure 2-11: Mechanistic Overview Of Anticancer Peptides
Figure 2-12: Functional Roles Of Tumor-Targeting Peptides & Cell-Penetrating Peptides In Cancer Therapy
Figure 2-13: Major Internalization Pathways Of Cell-Penetrating Peptides
Figure 2-14: Design Of Bifunctional Peptide Constructs
Figure 2-15: Activatable Cell-Penetrating Peptide Strategy
Figure 2-16: Integration Of Peptides & Nanotechnology For Precision Oncology
Figure 2-17: Classification Of Receptor Antagonist & PPI-Modulating Peptides
Figure 2-18: Inhibition Of Oncogenic Protein–Protein Interactions
Figure 2-19: Modern Technologies For Peptide Discovery
Figure 2-20: Stabilization Of ?-Helical Peptides By Stapling
Figure 2-21: Structural Advantages Of Cyclic Peptide Therapeutics
Figure 2-22: Foldamer-Based Mimics Of Protein Secondary Structures
Figure 2-23: Artificial Intelligence-Driven Next-Generation Peptide Design
Figure 3-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2024 - 2031
Figure 3-2: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2024 - 2031
Figure 3-3: Global Cancer Peptide Therapeutics Market – Future Opportunities
Figure 5-1: 17-328 Phase 1 (NCT03362060) Study – Initiation & Completion Year
Figure 5-2: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-3: PQ203-001 Phase 1 (NCT07190469) Study – Initiation & Completion Year
Figure 5-4: NCI-2014-02621 Phase 1 (NCT02334865) Study – Initiation & Completion Year
Figure 5-5: 20190675 Phase 1 (NCT04365179) Study – Initiation & Completion Year
Figure 5-6: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year
Figure 5-7: 202412028 Phase 1 (NCT06529822) Study – Initiation & Completion Year
Figure 5-8: PRMC 20-027 Phase 1 (NCT05010200) Study – Initiation & Completion Year
Figure 5-9: TB001 Version 2.1_2024-10-25 Phase 1/2 (NCT06400160) Study – Initiation & Completion Year
Figure 5-10: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year
Figure 5-11: CFXX489A12101 Phase 1 (NCT06562192) Study – Initiation & Completion Year
Figure 5-12: CGCJ904A12101 Phase 1 (NCT07261631) Study – Initiation & Completion Year
Figure 5-13: NCI-2017-01781 Phase 1 (NCT03300817) Study – Initiation & Completion Year
Figure 5-14: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-15: NeoLIPA Phase 2 (NCT06651151) Study – Initiation & Completion Year
Figure 5-16: KEYNOTE-D18 Phase 3 (NCT05155254) Study – Initiation & Completion Year
Figure 5-17: ST316-101 Phase 1 (NCT05848739) Study – Initiation & Completion Year
Figure 5-18: FOG-001-101 Phase 1/2 (NCT05919264) Study – Initiation & Completion Year
Figure 5-19: RYZ801-101 Phase 1/2 (NCT06726161) Study – Initiation & Completion Year
Figure 5-20: AMPLIFY-7P Phase 1/2 (NCT05726864) Study – Initiation & Completion Year
Figure 5-21: CDMRP-CA170223 Phase 2 (NCT03796884) Study – Initiation & Completion Year
Figure 5-22: TH1902-CTR-0001 Phase 1 (NCT04706962) Study – Initiation & Completion Year
Figure 5-23: CBX-12-201 Phase 2 (NCT06315491) Study – Initiation & Completion Year
Figure 5-24: BT5528-100 Phase 1/2 (NCT04180371) Study – Initiation & Completion Year
Figure 5-25: RAD301.2022-001 Phase 1 (NCT05799274) Study – Initiation & Completion Year
Figure 5-26: NCI-2015-00694 Phase 2 (NCT02455557) Study – Initiation & Completion Year
Figure 5-27: INTERCEPT-H3 Phase 1 (NCT04808245) Study – Initiation & Completion Year
Figure 5-28: ViCTOry Phase 1 (NCT05609994) Study – Initiation & Completion Year
Figure 5-29: NeoVax Phase 1 (NCT02287428) Study – Initiation & Completion Year
Figure 5-30: PRiME Phase 1 (NCT03299309) Study – Initiation & Completion Year
Figure 5-31: ST101-101 Phase 1/2 (NCT04478279) Study – Initiation & Completion Year
Figure 6-1: Firmagon – Patent Issue & Expiration Years
Figure 6-2: Firmagon – Price Per Unit & Supply Of Powder For Subcutaneous Injection (US$), June’2026
Figure 6-3: Firmagon - Starting & Maintenance Dosage (mg)
Figure 6-4: Firmagon – Treatment Costs Of Initial Cycle & Maintenance Cycle (US$), June’2026
Figure 6-5: Eligard - Cost Of Subcutaneous Powder For Injection By Dose (US$), June’2026
Figure 6-6: Eligard – Recommended Dosage For Prostate Cancer On Monthly Basis (mg)
Figure 6-7: Eligard – Prostate Cancer Annual Treatment Cost By Dose (US$), June’2026
Figure 6-8: Lupron Sustained Release Preparation – Patent Issue & Expiration Year
Figure 6-9: Lupron – Price Of Lupron Depot Intramuscular Kits (US$), June’2026
Figure 6-10: Lupron – Price of Lupron Depot Intramuscular Powder By Dose (US$), June’2026
Figure 6-11: Lupron – Annual Treatment Costs By Intramuscular Kit Dose (US$), June’2026
Figure 6-12: Lupron – Annual Treatment Costs By Intramuscular Powder Dose (US$), June’2026
Figure 6-13: Gonax - Cost of Supply Of Powder For Subcutaneous Injection (US$), June’2026
Figure 6-14: Gonax - Starting & Maintenance Dosage (mg)
Figure 6-15: Trelstar – Patent Issue & Expiration Year
Figure 6-16: Trelstar - Cost Per Unit & Supply Of Powder For Intramuscular Injection (US$), June’2026
Figure 6-17: Trelstar – Annual Treatment Cost By Dose (US$), June’2026
Figure 6-18: Decapeptyl SR – Price For A Supply of 3mg, 11.25mg & 22.5mg Powder For Injection (GBP/US$), June’2026
Figure 6-19: Decapeptyl SR - Recommended Dosage For Prostate Cancer (mg/week)
Figure 6-20: Decapeptyl SR - Annual Prostate Cancer Treatment Cost By Dose (US$), June’2026
Figure 6-21: Velcade – Price Of 3.5 mg Powder For Injection (US$), June’2026
Figure 6-22: Bortizomib – Price Of Injectable Powder For Injection By Dose (US$), June’2026
Figure 6-23: Ninlaro – Patent Issue & Expiration Year
Figure 6-24: US & EU – Price Per Unit & Supply Of Ninlaro Capsule (US$), June’2026
Figure 6-25: Ninlaro – Recommended Dose & Dose Reductions For Multiple Myeloma Treatment (mg/week)
Figure 6-26: Kyprolis – Price Of 10mg, 30mg & 60mg Intravenous Powder For Injection (US$), June’2026
Figure 6-27: Kyprolis – Initial Dose & Maintenance Dose For Multiple Myeloma Treatment (mg/m2/week)
Figure 6-28: Kyprolis - Initial Dose & Maintenance Dose As Monotherapy For Multiple Myeloma Treatment (mg/m2 Twice a Week)
Figure 6-29: Romidepsin – FDA Approval Year By Indication
Figure 6-30: Istodax & Romidepsin – Price Per Supply Of Intravenous Powder (US$), June’2026
Figure 6-31: Zoladex - Cost Of Implant By Dose (US$), June’2026
Figure 6-32: Zoladex – Recommended Dose For Prostate Cancer Management On Monthly Basis (mg/week)
Figure 6-33: Zoladex – Annual Treatment Cost Using 3.6mg & 10.8mg Implant (US$), June’2026
Figure 6-34: Dactinomycin – Price For Generic & Branded 0.5 mg Powder For Injection (US$), June’2026
Figure 6-35: Somatuline Depot – Price Per Unit & supply of Subcutaneous Solution By Dose (US$), June’2026
Figure 6-36: Lanreotide – Price Per Unit & Supply Of Subcutaneous Solution (US$), June’2026
Figure 6-37: Somatuline Depot – Treatment Cost Of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), June’2026
Figure 6-38: Sandostatin – Price Per Unit & 10-Vial Supply By Dose (US$), June’2026
Figure 6-39: Sandostatin LAR – Price Of Intramuscular Powder For Injection By Dose (US$), June’2026
Figure 6-40: Octreotide – Price Per Unit & Supply Of 10 mL Injectable Solution (US$), June’2026
Figure 6-41: Octreotide – Price Per Unit & Supply Of 5 mL Injectable Solution (US$), June’2026
Figure 6-42: Octreotide – Price Per Unit & Supply Of Intramuscular Powder For Injection By Dose (US$), June’2026
Figure 6-43: Sandostatin - Mean Initial Dose For Treatment Of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg/day)
Figure 6-44: Bynfezia Pen – Patent Issue & Expiration Year
Figure 6-45: Bynfezia Pen – Price Per Unit & Supply Of Subcutaneous Solution (US$), June’2026
Figure 6-46: Bynfezia Pen – Mean Dose For First 2 Week & Subsequent Weeks (mcg/day)
Figure 6-47: Lutathera – Patent Issue & Expiration Years
Figure 6-48: Lutathera – RDP & ODE Regional Expiry Years
Figure 6-49: Mepact - Recommended Number Of Dose Administration/Week for 12 & 24 Weeks Treatment
Figure 7-1: Kyprolis – Global Sales (US$ Million), 2020-2026
Figure 7-2: Kyprolis – Global Sales By Region (US$ Million), Q1’2026
Figure 7-3: Kyprolis – Global Sales By Region (US$ Million), 2025
Figure 7-4: Kyprolis - US Annual Sales (US$ Million), 2020-2026
Figure 7-5: Kyprolis - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-6: Zoladex - Global Sales (US$ Million), 2020-2026
Figure 7-7: Zoladex - Global Sales By Region (US$ Million), Q1’2026
Figure 7-8: Zoladex - Global Sales By Region (US$ Million), 2025
Figure 7-9: Zoladex - US Annual Sales (US$ Million), 2020-2026
Figure 7-10: Zoladex – Europe Annual Sales (US$ Million), 2020-2026
Figure 7-11: Zoladex – Emerging Markets Annual Sales (US$ Million), 2020-2026
Figure 7-12: Zoladex - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-13: Lutathera - Global Sales (US$ Million), 2020-2026
Figure 7-14: Lutathera - Global Sales By Region (US$ Million), 2024–2026
Figure 7-15: Lutathera – Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-16: Lutathera - US Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-17: Lutathera - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-18: Sandostatin - Global Sales (US$ Million), 2020-2026
Figure 7-19: Sandostatin - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-20: Sandostatin - US Annual Sales (US$ Million), 2020-2026
Figure 7-21: Sandostatin - US Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-22: Sandostatin - ROW Annual Sales (US$ Million), 2020-2026
Figure 7-23: Sandostatin - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-24: Somatuline – Global Sales (US$ Million), 2020-2026
Figure 7-25: Somatuline - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-26: Somatuline – North America Sales (US$ Million), 2022-2026
Figure 7-27: Somatuline - NA Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-28: Somatuline – Europe Sales (US$ Million), 2022-2026
Figure 7-29: Somatuline - Europe Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-30: Somatuline – ROW Sales (US$ Million), 2022-2026
Figure 7-31: Somatuline - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-32: Decapeptyl – Global Sales (US$ Million), 2020-2026
Figure 7-33: Decapeptyl - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-34: Decapeptyl – Europe Sales (US$ Million), 2022-2026
Figure 7-35: Decapeptyl - Europe Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-36: Decapeptyl – ROW Sales (US$ Million), 2022-2026
Figure 7-37: Decapeptyl - ROW Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-38: Ninlaro – Global Sales (US$ Million), 2020-2026
Figure 7-39: Ninlaro - Global Quarterly Sales (US$ Million), Q1-Q4’2025
Figure 7-40: Velcade - Global Sales (US$ Million), 2020-2024
Figure 7-41: Velcade - Global Quarterly Sales (US$ Million), Q1-Q4’2023
Figure 7-42: Global - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-43: US - Lupron Annual Sales (US$ Million), 2019-2021
Figure 7-44: ROW - Lupron Annual Sales (US$ Million), 2019-2021
Figure 8-1: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2026
Figure 10-1: Venom-Derived Peptides In Cancer Therapy
Figure 10-2: Bee Venom-Derived Peptides In Cancer Therapy
Figure 10-3: Melittin - Mechanism Of Action
Figure 10-4: Scorpion Venom-Derived Peptides In Cancer Therapy
Figure 10-5: Hallmarks Of Cancer Targeted By Scorpion Venom Peptides
Figure 10-6: Snake Venom-Derived Peptides As Anticancer Agents
Figure 10-7: Spider Venom-Derived Peptides In Cancer Therapy
Figure 10-8: Nanotechnology-Enhanced Lycosin-I Therapy
Figure 10-9: Cone Snail Venom-Derived Peptides In Cancer Therapy
Figure 11-1: Global Peptide Cancer Drug Market - Drivers & Opportunities
Figure 11-2: Global Peptide Cancer Drug Market - Key Challenges & Corresponding Solutions
Figure 12-1: Classification & Molecular Targets of Anticancer Therapeutic Peptides
Figure 12-2: Therapeutic Peptide Targets In Cancer Signal Transduction Networks
Figure 12-3: Cell Cycle & Major Peptide Intervention Points
Figure 12-4: Checkpoint & Mitotic Targets For Therapeutic Peptides
Figure 12-5: Major Peptide Targets In Apoptosis Signaling
Figure 12-6: BH3 Mimetic Mechanism
Figure 12-7: Transcription Factor-Targeting Peptides In Cancer
Figure 12-8: Mechanisms Of Peptide Inhibition Of Transcription Factors
Figure 12-9: Dominant-Negative Peptide Strategy
Figure 12-10: Challenges & Solutions In Transcription Factor Peptide Therapy
Figure 12-11: DNA Damage Response & Sites Of Peptide Intervention
Figure 12-12: Synthetic Lethality In DNA Repair
Figure 12-13: Anti-Angiogenic Peptides – Examples
Figure 12-14: Anti-Angiogenic Peptides - Classification
Figure 12-15: Overall Mechanism Of Immunomodulatory Peptides
Figure 12-16: Dual Action Pathway
Figure 12-17: Membrane-Disrupting Peptides - Overall Mechanism
Figure 12-18: Cancer Selectivity Mechanism
List Of Tables
Table 1-1: Source Or Chemical Nature Of Early Peptides
Table 2-1: Classification Of Hormonal Peptide Therapeutics
Table 2-2: Major Receptor Targets For Peptide Radionuclide Delivery
Table 2-3: Types Of Peptide Cancer Vaccines
Table 2-4: Common Cytotoxic Payloads
Table 2-5: Types Of Peptide-Based Drug Delivery Systems
Table 2-6: Classification Of Cell-Penetrating Peptides
Table 2-7: Comparison Between TTPs & CPPs
Table 2-8: Stimuli-Responsive Peptide Nanomedicine Systems
Table 2-9: Nanocarrier Platforms In Peptide Nanomedicine
Table 2-10: Comparison Of Conventional Drug Delivery & Peptide Nanomedicine
Table 2-11: Peptide Engineering Strategies For PPI Inhibitors
Table 2-12: Types Of PPI-Modulating Peptides
Table 2-13: Comparison Of PPI-Modulating Peptides & Receptor Antagonist Peptides
Table 2-14: Limitations Addressed By Emerging Peptide Therapeutics
Table 2-15: Comparison Of Emerging Peptide Platforms
Table 2-16: Artificial Intelligence Tools In Peptide Design
Table 2-17: Advantages Of AI-Guided Peptide Discovery
Table 3-1: Global Cancer Peptide Therapeutics Market – Recent Fundings & Investments
Table 3-2: Global Cancer Peptide Therapeutics Market – Recent Collaborations
Table 6-1: Trelstar - Recommended Dose (mg/week)
Table 6-2: Velcade - Dosage Regimen For Patients With Previously Untreated Multiple Myeloma
Table 6-3: Kyprolis –Expiration Year Of Patents
Table 10-1: Broad Classification Of Venom Sources For ACPs
Table 10-2: Most Common Venom Sources Investigated For Anticancer Peptides
Table 10-3: Well-Known Venom-Derived Anticancer Peptides & Their Mechanisms
Table 10-4: Major Bee Venom Peptides & Their Anticancer Functions
Table 10-5: Major Scorpion Venom Peptides & Their Anticancer Activities
Table 10-6: Major Snake Venom-Derived Anticancer Peptides
Table 10-7: Major Spider Venom-Derived Anticancer Peptides
Table 10-8: Major Cone Snail Venom Peptides & Anticancer Activities
Table 12-1: MAPK Signaling Components Targeted By Therapeutic Peptides
Table 12-2: Major Signal Transduction Pathways & Their Cancer Functions
Table 12-3: Delivery & Engineering Strategies For Cell Cycle Peptides
Table 12-4: DNA Repair Targets & Therapeutic Outcomes
Table 12-5: Types Of Immunomodulatory Peptides
